UNLABELLED: We evaluated the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP). One hundred seven patients were enrolled. Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery (CRp) of 5%. The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies. BACKGROUND: The purpose of this study was to evaluate the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP). PATIENTS AND METHODS: One hundred seven patients with refractory/relapsed AML, intermediate and high-risk MDS, and CML-BP, with a performance status of 3 or less and normal organ function were treated. Patients received fludarabine 15 mg/m(2) intravenously (IV) every 12 hours on days 1 to 5 and cytarabine 0.5 g/m(2) IV over 2 hours every 12 hours on days 1 to 5. Gemtuzumab ozogamicin (GO) was administered at 3 mg/m(2) IV on day 1 in the first 59 patients. Patients with CML-BP were allowed to receive concomitant tyrosine kinase inhibitors. RESULTS: Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery of 5%. The overall 4-week mortality rate was 9%. The CR rates for patients with relapsed AML with first CR duration greater than or equal to 12 months, relapsed AML with first CR duration less than 12 months, and refractory/relapsed AML beyond first salvage were 56%, 26%, and 11%, respectively. With a median follow-up of 7 months, the 6-month event-free survival, overall survival, and complete remission CR duration rates were 18%, 35%, and 70%, respectively. CONCLUSION: BIDFA is active with an overall response rate of 26% in a heavily pretreated population. This combination is safe with a low 4-week mortality rate of 9%.
UNLABELLED: We evaluated the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP). One hundred seven patients were enrolled. Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery (CRp) of 5%. The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies. BACKGROUND: The purpose of this study was to evaluate the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP). PATIENTS AND METHODS: One hundred seven patients with refractory/relapsed AML, intermediate and high-risk MDS, and CML-BP, with a performance status of 3 or less and normal organ function were treated. Patients received fludarabine 15 mg/m(2) intravenously (IV) every 12 hours on days 1 to 5 and cytarabine 0.5 g/m(2) IV over 2 hours every 12 hours on days 1 to 5. Gemtuzumab ozogamicin (GO) was administered at 3 mg/m(2) IV on day 1 in the first 59 patients. Patients with CML-BP were allowed to receive concomitant tyrosine kinase inhibitors. RESULTS: Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery of 5%. The overall 4-week mortality rate was 9%. The CR rates for patients with relapsed AML with first CR duration greater than or equal to 12 months, relapsed AML with first CR duration less than 12 months, and refractory/relapsed AML beyond first salvage were 56%, 26%, and 11%, respectively. With a median follow-up of 7 months, the 6-month event-free survival, overall survival, and complete remission CR duration rates were 18%, 35%, and 70%, respectively. CONCLUSION:BIDFA is active with an overall response rate of 26% in a heavily pretreated population. This combination is safe with a low 4-week mortality rate of 9%.
Authors: Richard A Larson; Eric L Sievers; Edward A Stadtmauer; Bob Löwenberg; Elihu H Estey; Hervé Dombret; Matthias Theobald; Dimitris Voliotis; John M Bennett; Maria Richie; Lance H Leopold; Mark S Berger; Matthew L Sherman; Michael R Loken; Jacques J M van Dongen; Irwin D Bernstein; Frederick R Appelbaum Journal: Cancer Date: 2005-10-01 Impact factor: 6.860
Authors: Hagop Kantarjian; Varsha Gandhi; Jorge Cortes; Srdan Verstovsek; Min Du; Guillermo Garcia-Manero; Francis Giles; Stefan Faderl; Susan O'Brien; Sima Jeha; Jan Davis; Zeev Shaked; Adam Craig; Michael Keating; William Plunkett; Emil J Freireich Journal: Blood Date: 2003-06-05 Impact factor: 22.113
Authors: Nicholas J Short; Hagop Kantarjian; Farhad Ravandi; Xuelin Huang; Lianchun Xiao; Guillermo Garcia-Manero; William Plunkett; Varsha Gandhi; Koji Sasaki; Naveen Pemmaraju; Naval G Daver; Gautam Borthakur; Nitin Jain; Marina Konopleva; Zeev Estrov; Tapan M Kadia; William G Wierda; Courtney D DiNardo; Mark Brandt; Susan M O'Brien; Jorge E Cortes; Elias Jabbour Journal: Leuk Lymphoma Date: 2017-07-18
Authors: Prajwal Boddu; Hagop M Kantarjian; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Elias Jabbour; Gautam Borthakur; Marina Konopleva; Kapil N Bhalla; Naval Daver; Courtney D DiNardo; Christopher B Benton; Koichi Takahashi; Zeev Estrov; Sherry R Pierce; Michael Andreeff; Jorge E Cortes; Tapan M Kadia Journal: Blood Adv Date: 2017-07-19
Authors: Massimiliano Bonifacio; Fabio Stagno; Luigi Scaffidi; Mauro Krampera; Francesco Di Raimondo Journal: Front Oncol Date: 2019-10-25 Impact factor: 6.244
Authors: Geoffrey L Uy; Ibrahim Aldoss; Matthew C Foster; Peter H Sayre; Matthew J Wieduwilt; Anjali S Advani; John E Godwin; Martha L Arellano; Kendra L Sweet; Ashkan Emadi; Farhad Ravandi; Harry P Erba; Michael Byrne; Laura Michaelis; Max S Topp; Norbert Vey; Fabio Ciceri; Matteo Giovanni Carrabba; Stefania Paolini; Gerwin A Huls; Mojca Jongen-Lavrencic; Martin Wermke; Patrice Chevallier; Emmanuel Gyan; Christian Récher; Patrick J Stiff; Kristen M Pettit; Bob Löwenberg; Sarah E Church; Erica Anderson; Jayakumar Vadakekolathu; Marianne Santaguida; Michael P Rettig; John Muth; Teia Curtis; Erin Fehr; Kuo Guo; Jian Zhao; Ouiam Bakkacha; Kenneth Jacobs; Kathy Tran; Patrick Kaminker; Maya Kostova; Ezio Bonvini; Roland B Walter; Jan K Davidson-Moncada; Sergio Rutella; John F DiPersio Journal: Blood Date: 2021-02-11 Impact factor: 25.476